{
    "id": 32439,
    "fullName": "TP53 R181E",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "TP53 R181E lies within the DNA-binding domain of the Tp53 protein (PMID: 21760703). R181E results in a loss of DNA binding ability and activation of downstream targets, increased accumulation of Tp53, and fails to induce apoptosis and inhibit proliferation in culture, and induces tumor formation in animal models (PMID: 31483066).",
            "references": [
                {
                    "id": 17774,
                    "pubMedId": 31483066,
                    "title": "Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31483066"
                },
                {
                    "id": 807,
                    "pubMedId": 21760703,
                    "title": "TP53 status and response to treatment in breast cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21760703"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7157,
        "geneSymbol": "TP53",
        "terms": [
            "TP53",
            "BCC7",
            "BMFS5",
            "LFS1",
            "P53",
            "TRP53"
        ]
    },
    "variant": "R181E",
    "createDate": "02/05/2020",
    "updateDate": "02/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 187529,
        "transcript": "NM_000546",
        "gDna": "chr17:g.7675069_7675071delGCGinsCTC",
        "cDna": "c.541_543delCGCinsGAG",
        "protein": "p.R181E",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20261,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nutlin-3 and Adriamycin (doxorubicin) combination treatment induced apoptosis, and inhibited proliferation and viability of transformed mouse cells expressing TP53 R181E in culture (PMID: 31483066).",
            "molecularProfile": {
                "id": 34972,
                "profileName": "TP53 R181E"
            },
            "therapy": {
                "id": 9299,
                "therapyName": "Doxorubicin + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17774,
                    "pubMedId": 31483066,
                    "title": "Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31483066"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20264,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RG7112 (RO5045337) and Adriamycin (doxorubicin) combination treatment induced cytotoxicity in transformed mouse cells expressing TP53 R181E in culture (PMID: 31483066).",
            "molecularProfile": {
                "id": 34972,
                "profileName": "TP53 R181E"
            },
            "therapy": {
                "id": 9305,
                "therapyName": "Doxorubicin + RG7112",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17774,
                    "pubMedId": 31483066,
                    "title": "Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31483066"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20260,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line expressing TP53 R181E demonstrated enhanced sensitivity to Adriamycin (doxorubicin) treatment when combined with Nutlin-3, and induced apoptosis in culture (PMID: 31483066).",
            "molecularProfile": {
                "id": 34972,
                "profileName": "TP53 R181E"
            },
            "therapy": {
                "id": 9299,
                "therapyName": "Doxorubicin + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17774,
                    "pubMedId": 31483066,
                    "title": "Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31483066"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20257,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nutlin-3 treatment did not induce apoptosis in transformed mouse cells expressing TP53 R181E in culture (PMID: 31483066).",
            "molecularProfile": {
                "id": 34972,
                "profileName": "TP53 R181E"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17774,
                    "pubMedId": 31483066,
                    "title": "Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31483066"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20262,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 and Adriamycin (doxorubicin) combination treatment induced cytotoxicity in transformed mouse cells expressing TP53 R181E in culture (PMID: 31483066).",
            "molecularProfile": {
                "id": 34972,
                "profileName": "TP53 R181E"
            },
            "therapy": {
                "id": 9306,
                "therapyName": "Doxorubicin + SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17774,
                    "pubMedId": 31483066,
                    "title": "Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31483066"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20263,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Idasanutlin (RG7388) and Adriamycin (doxorubicin) combination treatment induced cytotoxicity in transformed mouse cells expressing TP53 R181E in culture (PMID: 31483066).",
            "molecularProfile": {
                "id": 34972,
                "profileName": "TP53 R181E"
            },
            "therapy": {
                "id": 9304,
                "therapyName": "Doxorubicin + Idasanutlin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17774,
                    "pubMedId": 31483066,
                    "title": "Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31483066"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34972,
            "profileName": "TP53 R181E",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 187530,
            "transcript": "NM_001126113",
            "gDna": "chr17:g.7675069_7675071delGCGinsCTC",
            "cDna": "c.541_543delCGCinsGAG",
            "protein": "p.R181E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 187528,
            "transcript": "NM_001126112",
            "gDna": "chr17:g.7675069_7675071delGCGinsCTC",
            "cDna": "c.541_543delCGCinsGAG",
            "protein": "p.R181E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 187529,
            "transcript": "NM_000546",
            "gDna": "chr17:g.7675069_7675071delGCGinsCTC",
            "cDna": "c.541_543delCGCinsGAG",
            "protein": "p.R181E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 187531,
            "transcript": "NM_001126114",
            "gDna": "chr17:g.7675069_7675071delGCGinsCTC",
            "cDna": "c.541_543delCGCinsGAG",
            "protein": "p.R181E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}